Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of IMM2510 alone or with chemotherapy as first-line treatment for non-small cell lung cancer or triple-negative breast cancer
CTR20244810Phase 2Active
- Sponsor
- ImmuneOnco
- Start
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IMM2510 in non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), sponsored by ImmuneOnco. Started Dec 2024; status: active.
02
Drugs
IMM2510
03
Conditions
non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20244810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244810.